These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 22873097)
1. Normal serum CA125 half-life and normal serum nadir CA125 level in patients with ovarian cancers. Yoshikawa T; Takano M; Kita T; Kudoh K; Sasaki N; Kato M; Watanabe A; Miyamoto M; Goto T; Furuya K Eur J Gynaecol Oncol; 2012; 33(3):269-73. PubMed ID: 22873097 [TBL] [Abstract][Full Text] [Related]
2. Vascular endothelial growth factor expression correlates with serum CA125 and represents a useful tool in prediction of refractoriness to platinum-based chemotherapy and ascites formation in epithelial ovarian cancer. Masoumi-Moghaddam S; Amini A; Wei AQ; Robertson G; Morris DL Oncotarget; 2015 Sep; 6(29):28491-501. PubMed ID: 26143638 [TBL] [Abstract][Full Text] [Related]
3. Prognostic value of CA125 kinetics and half-life in advanced ovarian cancer. Colaković S; Lukiç V; Mitroviç L; Jeliç S; Susnjar S; Marinkoviç J Int J Biol Markers; 2000; 15(2):147-52. PubMed ID: 10883888 [TBL] [Abstract][Full Text] [Related]
4. CA125 decline in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapy. Richardson DL; Seamon LG; Carlson MJ; O'Malley DM; Fowler JM; Copeland LJ; Cohn DE Gynecol Oncol; 2008 Nov; 111(2):233-6. PubMed ID: 18768214 [TBL] [Abstract][Full Text] [Related]
5. The significance of the change pattern of serum CA125 level for judging prognosis and diagnosing recurrences of epithelial ovarian cancer. Yang ZJ; Zhao BB; Li L J Ovarian Res; 2016 Sep; 9(1):57. PubMed ID: 27629537 [TBL] [Abstract][Full Text] [Related]
7. Perioperative changes in serum CA125 levels: a prognostic factor for disease-specific survival in patients with ovarian cancer. Zwakman N; van de Laar R; Van Gorp T; Zusterzeel PL; Snijders MP; Ferreira I; Massuger LF; Kruitwagen RF J Gynecol Oncol; 2017 Jan; 28(1):e7. PubMed ID: 27670261 [TBL] [Abstract][Full Text] [Related]
8. [Potential value of CA125 kinetic monitoring in the initial management of advanced epithelial ovarian cancer]. Vignot S; Brochet C; Debord C; Lauratet B; Bernard M Ann Biol Clin (Paris); 2011; 69(5):597-604. PubMed ID: 22008142 [TBL] [Abstract][Full Text] [Related]
9. The significance of the pattern of serum CA125 level ascent to above the normal range in epithelial ovarian, primary peritoneal and tubal carcinoma patients. Levy T; Weiser R; Boaz M; Ben Shem E; Golan A; Menczer J Gynecol Oncol; 2013 Apr; 129(1):165-8. PubMed ID: 23274778 [TBL] [Abstract][Full Text] [Related]
10. Clinical Significance of CA125 Level after the First Cycle of Chemotherapy on Survival of Patients with Advanced Ovarian Cancer. Lee M; Chang MY; Yoo H; Lee KE; Chay DB; Cho H; Kim S; Kim YT; Kim JH Yonsei Med J; 2016 May; 57(3):580-7. PubMed ID: 26996555 [TBL] [Abstract][Full Text] [Related]
11. Diagnostic Model of Serum miR-193a-5p, HE4 and CA125 Improves the Diagnostic Efficacy of Epithelium Ovarian Cancer. Ren X; Zhang H; Cong H; Wang X; Ni H; Shen X; Ju S Pathol Oncol Res; 2018 Oct; 24(4):739-744. PubMed ID: 29520570 [TBL] [Abstract][Full Text] [Related]
12. CA125 nadir concentration is an independent predictor of tumor recurrence in patients with ovarian cancer: a population-based study. van Altena AM; Kolwijck E; Spanjer MJ; Hendriks JC; Massuger LF; de Hullu JA Gynecol Oncol; 2010 Nov; 119(2):265-9. PubMed ID: 20797777 [TBL] [Abstract][Full Text] [Related]
13. Does serum CA125 have clinical value for follow-up monitoring of postoperative patients with epithelial ovarian cancer? Results of a 12-year study. Guo N; Peng Z J Ovarian Res; 2017 Mar; 10(1):14. PubMed ID: 28284216 [TBL] [Abstract][Full Text] [Related]
14. CA125 surveillance increases optimal resectability at secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Fleming ND; Cass I; Walsh CS; Karlan BY; Li AJ Gynecol Oncol; 2011 May; 121(2):249-52. PubMed ID: 21300398 [TBL] [Abstract][Full Text] [Related]
15. The utility of presurgical CA125 to predict optimal tumor cytoreduction of epithelial ovarian cancer. Barlow TS; Przybylski M; Schilder JM; Moore DH; Look KY Int J Gynecol Cancer; 2006; 16(2):496-500. PubMed ID: 16681717 [TBL] [Abstract][Full Text] [Related]
16. Primary peritoneal cancer: study of 14 cases and comparison with epithelial ovarian cancer. Fukuda T; Imai K; Yamauchi M; Teramae M; Hashiguchi Y; Ichimura T; Yasui T; Sumi T Eur J Gynaecol Oncol; 2015; 36(1):49-53. PubMed ID: 25872334 [TBL] [Abstract][Full Text] [Related]
17. Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated Guidelines From the European Group on Tumor Markers. Sölétormos G; Duffy MJ; Othman Abu Hassan S; Verheijen RH; Tholander B; Bast RC; Gaarenstroom KN; Sturgeon CM; Bonfrer JM; Petersen PH; Troonen H; CarloTorre G; Kanty Kulpa J; Tuxen MK; Molina R Int J Gynecol Cancer; 2016 Jan; 26(1):43-51. PubMed ID: 26588231 [TBL] [Abstract][Full Text] [Related]
18. Diagnostic performance of the biomarkers HE4 and CA125 in type I and type II epithelial ovarian cancer. Kristjansdottir B; Levan K; Partheen K; Sundfeldt K Gynecol Oncol; 2013 Oct; 131(1):52-8. PubMed ID: 23891789 [TBL] [Abstract][Full Text] [Related]
19. Vascular endothelial growth factor (VEGF) improves the sensitivity of CA125 for differentiation of epithelial ovarian cancers from ovarian cysts. Robati M; Ghaderi A; Mehraban M; Shafizad A; Nasrolahi H; Mohammadianpanah M Arch Gynecol Obstet; 2013 Oct; 288(4):859-65. PubMed ID: 23564055 [TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of human epididymis protein 4 in epithelial ovarian cancer. Paek J; Lee SH; Yim GW; Lee M; Kim YJ; Nam EJ; Kim SW; Kim YT Eur J Obstet Gynecol Reprod Biol; 2011 Oct; 158(2):338-42. PubMed ID: 21683503 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]